Skip to main content

Table 2 Clinical characteristics of patients

From: Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

Patient Age in years Gender Disease duration in years Anti-SSA/Anti-SSB/RF Extraglandular manifestations Prednisolone (mg/day) Adverse events
1a 59 Female 13 +/+/+ Arthralgia - Vertigo, perspiration
2 46 Female 12 +/+/+ LP, RS - GI discomfort, common cold
3a 50 Female 15 +/+/+ Arthralgia, RS, LP - GI discomfort
4 67 Female 17 +/+/+ Arthralgia, RS 2.5 None
5 60 Female 4 +/+/+ Arthralgia, LP, VA - GI discomfortb
6a 61 Female 5 +/+/+ Arthralgia, LP - Pneumonia
7 53 Female 13 +/-/+ LP, PNP 2.5 GI discomfort, herpes labialis
8 40 Female 2 +/-/- Arthralgia, LP - None
9 35 Female 12 +/-/+ LP, RS 5 None
10 44 Female 9 +/+/+ Arthralgia, RS - Palpitation, perspirationb
11 36 Female 2 +/+/- Arthralgia - Common cold
  1. aPatients 1, 3, and 6 did not complete the study; bdose was reduced to 720 mg/day after week 12. GI, gastrointestinal; LP, leukopenia; PNP, polyneuropathy; RF, rheumatoid factor; RS, Raynaud syndrome; VA, vasculitis.